Is Hamps Bio overvalued or undervalued?

As of 8 September 2025, Hamps Bio's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its valuation perception. The company appears to be overvalued based on its current metrics. Key ratios include a PE ratio of 13.07, an EV to EBIT of 15.94, and a ROCE of 3.34%.
In comparison to its peers, Hamps Bio's valuation is significantly lower than that of Sun Pharma, which has a PE ratio of 33.03, and Divi's Lab, with a PE ratio of 69.52. Other peers like Cipla and Dr. Reddy's Labs, which are rated attractive, have PE ratios of 23.12 and 18.41, respectively. Despite a recent uptick in stock performance compared to the Sensex over the past week, the year-to-date return of -27.42% suggests that Hamps Bio remains overvalued in the current market context.